Abstracts tagged "autoimmune diseases"

Abstract Number: 0035 • ACR Convergence 2020
Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides
Loqmane Seridi¹, Matteo Cesaroni¹, Qingxuan Song², Ashley Orillion¹, Frédéric Baribaud¹, Tatiana Ort¹, Sheng Gao², Tomas Parker³, James Chevalier³, Dan Levine³, Alan Perlman³ and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ³The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY
Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN…
Abstract Number: 0395 • ACR Convergence 2020
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
Julia Hartman¹, Andrea Conte², Chloe Borden³, Urvashi Kaundal⁴, Yongbing Zhao², Sarah Safran⁵, Ami Shah⁶, Maureen Mayes⁷, Ayo Doumatey⁸, Amy Bentley⁹, Daniel Shriner⁸, Robyn Domsic¹⁰, Thomas Medsger¹¹, Paula Ramos¹², Richard Silver¹³, Virginia Steen¹⁴, John Varga¹⁵, Vivien Hsu¹⁶, Lesley Ann Saketkoo¹⁷, Elena Schiopu¹⁸, Dinesh Khanna¹⁹, Jessica Gordon²⁰, Lindsey Criswell²¹, Heather Gladue²², Chris Derk²³, Elana Bernstein²⁴, S. Louis Bridges²⁵, Victoria Shanmugam²⁶, Kathleen Kolstad²⁷, Lorinda Chung²⁸, Suzanne Kafaja²⁹, Reem Jan³⁰, Marcin Trojanowski³¹, Avram Goldberg³², Benjamin Korman³³, Monique Hinchcliff³⁴, Settara Chandrasekharappa⁸, Stefania Dell'Orso³, Adebowale Adeyemo⁸, Charles Rotimi⁸, Elaine Remmers³⁵, Fredrick Wigley³⁶, Daniel Kastner³⁵, Francesco Boin³⁷, Rafael Casellas² and Pravitt Gourh⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, ⁶Johns Hopkins University School of Medicine, Ellicott City, MD, ⁷University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁸National Human Genome Research Institute, Bethesda, ⁹National Human Genome Research Institute (NHGRI), NIH, Bethedsa, MD, ¹⁰University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹¹University of Pittsburgh School of Medicine, Verona, PA, ¹²Medical University of South Carolina, Charleston, SC, ¹³Medical University of South Carolina, Charleston, ¹⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁵Northwestern University, Chicago, IL, ¹⁶Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁷Scleroderma Patient Care and Research Center, Tulane University, New Orleans, LA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Hospital for Special Surgery, New York, NY, ²¹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ²²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Columbia University, New York, NY, ²⁵University of Alabama at Birmingham, Mountain Brk, AL, ²⁶The George Washington University, Washington, DC, ²⁷Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ²⁹David Geffen School of Medicine, UCLA, Los Angeles, CA, ³⁰Pritzker School of Medicine, University of Chicago, Chicago, IL, ³¹Boston University Medical Center, BOSTON, MA, ³²NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ³³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³⁴Yale School of Medicine, Westport, CT, ³⁵National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ³⁶Johns Hopkins University School of Medicine, Baltimore, MD, ³⁷University of California San Francisco, Cedars-Sinai, West Hollywood, CA
Background/Purpose: African American (AA) patients have a higher prevalence of SSc than European Americans (EA). Adding to this health disparity, AA SSc patients are more…
Abstract Number: 0595 • ACR Convergence 2020
High Satisfaction with Tele-medicine in a New York City Clinic
Tommy Chen¹, Cathy Guo¹, Wei Tang¹, Leila Khalili¹ and Anca Askanase², ¹Columbia University Medical Center, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: The face of medicine is changing with the time. A twenty-first century technological revolution in medicine happened in March 2020 as the COVID-19 pandemic…
Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Teun van Gelder¹, Robert Huizinga², Neil Solomons² and Laura Lisk³, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
Abstract Number: 1052 • ACR Convergence 2020
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Joanna Marco¹ and Elizabeth Ferucci², ¹University of Washington, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
Abstract Number: 1307 • ACR Convergence 2020
Detecting Subtle Changes in Fundoscopic Retinal Images in Patients with Axial Spondyloarthritis with Deep Learning
Yun Ju Huang¹, Chang-Fu Kuo², Yu Huei Huang³, Yih Shiou Hwang⁴ and Chihung Lin⁵, ¹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan (Republic of China), ²Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ³Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), ⁴Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China)
Background/Purpose: Fundoscopy is essential to identify the retinopathy of patients with autoimmune diseases. However, the classification of different autoimmune diseases is difficult by human eyes…
Abstract Number: 1471 • ACR Convergence 2020
Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study
Jill Hahn¹, May Choi², Susan Malspeis³, Emma Stevens⁴, Elizabeth Karlson⁴, Kazuki Yoshida⁵, Laura Kubzansky⁶, Jeffrey Sparks⁷ and Karen Costenbader⁸, ¹Brigham and Womens' Hospital, Newton, MA, ²Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Many potentially modifiable biobehavioral factors have been associated with the risk of developing rheumatoid arthritis (RA), but the benefit of adopting an overall healthy…
Abstract Number: 1750 • ACR Convergence 2020
Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Larissa Valor Mendez², Verena Schoenau³, Marina Sergeeva⁴, Jutta Prade⁴, Mageshvar Sulvakumar⁵, Laura Konert⁶, Arnd Kleyer¹, David Simon¹, Sandra Strobelt⁴, Frank Behrens⁷, Christoph Baerwald⁸, Stephanie Finzel⁹, Reinhard Voll¹⁰, Axel Hueber¹¹, Eugen Feist¹², Julie Roesch¹³, José A. P. da Silva¹⁴, Arnd Doerfler¹³, Nemanja Damjanov¹⁵, Andreas Hess¹⁶ and Georg Schett¹⁷, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, ⁶Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, ⁷CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁸Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ¹⁰Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹¹Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹⁴9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁵Belgrade University School of Medicine, Belgrade, Serbia, ¹⁶Institute for Experimental Pharmacology, Erlangen, ¹⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
Abstract Number: PP05 • ACR Convergence 2020
Coping Through Advocacy – My Story Living with Relapsing Polychondritis
Allegonda Imeson¹, ¹The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada
Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two…
Abstract Number: 0037 • ACR Convergence 2020
Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
Adrianos Nezos¹, Eleni Kotsifaki¹, Charalampos Skarlis², Konstantinos Markakis¹, Haralampos Moutsopoulos³, Michael Koutsilieris¹, Clio Mavragani¹ and Anna Psarrou¹, ¹National & Kapodistrian University of Athens, Athens, Greece, ²National &Kapodistrian University of Athens, Athens, Greece, ³National & Kapodistrian University of Athens/ Academy of Athens, Athens, Greece
Background/Purpose: B-cell non-Hodgkin's lymphoma (B-NHL) is one of the major complications of primary Sjögren’s syndrome (SS). Chronic inflammation and macrophages in SS minor salivary glands…
Abstract Number: 0417 • ACR Convergence 2020
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
Eduardo Martin-Nares¹, Janette Furuzawa-Carballeda¹, Ángel Alexis Priego-Ranero¹, Isela Chan-Campos¹, Gladys Sulikey Herrera-Noguera¹, Fidel López-Verdugo¹ and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico
Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are…
Abstract Number: 0606 • ACR Convergence 2020
A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease
Alexandra Nelson¹ and Marina Anderson², ¹University of Liverpool, Liverpool, United Kingdom, ²Lancaster University, Lancaster, United Kingdom
Background/Purpose: Recent advancements in the delivery and utilization of information and communication technologies (ICTs) have led to an increased application of telehealthcare services. Global coronavirus…
Abstract Number: 0866 • ACR Convergence 2020
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies
Joan Merrill¹, Matthew Studham², Eric Morand³, Aida Aydemir², Cristina Vazquez Mateo², Alex Rolfe², Amy Kao² and Robert Townsend², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
Abstract Number: 1054 • ACR Convergence 2020
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients
José Luis Martín-Varillas¹, Vanesa Calvo-Río², Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon³, Ignacio Torre⁴, Alvaro García Martos⁵, Amalia Sánchez Andrade⁶, Angel García Aparicio⁷, Juan Ramón De dios⁸, Ana Urriticoechea⁹, Olga Maiz Alonso¹⁰, Raul Veroz¹¹, Andrea García Valle¹², Sergio Rodriguez Montero¹³, Roberto Miguelez¹⁴, Vega Jovani¹⁵, Marisa Hernandez Garfella¹⁶, Arantxa Conesa¹⁷, Olga Martinez Gonzalez¹⁸, Paula Rubio Muñoz¹⁹, Eva Peña Sainz-Pardo²⁰, Miguel Ángel González-Gay²¹ and Ricardo Blanco², ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Basurto, Bilbao, Spain, ⁵Hospital del Tajo, Madrid, Spain, ⁶H. Lucus Augusti, Lugo, Spain, ⁷H. Mostoles, Madrid, Spain, ⁸H. Alava, Alava, Spain, ⁹Can Misses, Ibiza, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹H. Mérida, Mérida, Spain, ¹²H. Palencia, Palencia, Spain, ¹³H. Virgen de Valme, Sevilla, Spain, ¹⁴Toledo, Toledo, Spain, ¹⁵H. Alicante, Alicante, Spain, ¹⁶H. Valencia, Valencia, Spain, ¹⁷H. Castellón, Castellón, ¹⁸H. Salamanca, Salamanca, ¹⁹H. Esperit Sant, Barcelona, Spain, ²⁰H. 12 de Octubre, Madrid, Spain, ²¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…
Abstract Number: 1379 • ACR Convergence 2020
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Robyn Domsic¹, Lorinda Chung², Jerry Molitor³, Robert Spiera⁴, Bradley Bloom⁵, Barbara White⁶ and Quinn Dinh⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ³University of Minnesota, Minneapolis, MN, ⁴Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁵Corbus Pharmaceuticals Inc, Norwood, MA, ⁶Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].